Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04478474 · ClinicalTrials.gov registry record

Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients

A clinical trial, sponsored by New York Medical College.

Completed
Registry status
100
Enrollment target

NCT04478474 is a clinical trial that has completed, run by New York Medical College. The registered enrollment target is 100 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04478474 has completed, sponsored by New York Medical College.

COMPLETED
Registry status
100 participants
Enrollment target

Study Summary

The primary objective is to determine the incidence of CMV viremia and disease in pediatric allogeneic stem cell transplantation recipients who received ganciclovir prophylaxis up until day +100 by retrospective analysis.

Interventions

  • DRUG Ganciclovir

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2020-09-15
Est. Completion 2022-09-15

Sponsor

New York Medical College

47 total trials

What the Registry Record Tells You About NCT04478474

The ClinicalTrials.gov registry entry for NCT04478474 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Ganciclovir is the first listed.

NCT04478474 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04478474 about?

NCT04478474 is a clinical study titled "Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients". The primary objective is to determine the incidence of CMV viremia and disease in pediatric allogeneic stem cell transplantation recipients who received ganciclovir prophylaxis up until day +100 by retrospective analysis.

What is the current status of trial NCT04478474?

This trial is currently completed. The enrollment target is 100 participants. The study started on 2020-09-15. Estimated completion is 2022-09-15.

What interventions are being tested in trial NCT04478474?

The interventions under investigation include: Ganciclovir (DRUG).

Who is sponsoring clinical trial NCT04478474?

This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.